Epizyme gets FDA priority review for Tazverik to treat follicular lymphoma
Tazverik is indicated for relapsed or refractory FL in adult patients whose tumours are positive for an EZH2…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Jun 20
Tazverik is indicated for relapsed or refractory FL in adult patients whose tumours are positive for an EZH2…
17 Jun 20
The US FDA approval for Cosentyx is based on the Phase 3 PREVENT trial, which showed efficacy in…
The FDA has cited evidence of serious side-effects including cardiac-adverse events in patients given chloroquine drugs to treat…
16 Jun 20
Kynmobi demonstrated improvement in motor symptoms for patients with PD compared to placebo in Phase 3 clinical trial
16 Jun 20
Data from the Phase 3 randomised, active-controlled clinical studies PRONTO-T1D and PRONTO-T2D has supported the US regulatory approval…
15 Jun 20
Dolutegravir is an integrase strand transfer inhibitor which, in combination with other antiretroviral agents, has potential to treat…
11 Jun 20
Opdivo is indicated for unresectable advanced, metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy
08 Jun 20
FDA indicated Recarbrio for patients aged 18 years or older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia…
05 Jun 20
Daratumumab SC, administered as a fixed-dose, would reduce treatment time compared to daratumumab intravenous (IV) formulation
04 Jun 20
The regulatory approval is based on the Phase 3 BEACON CRC trial, which showed positive results for BRAFTOVI…